𝔖 Bobbio Scriptorium
✦   LIBER   ✦

458 FINAL RESULTS OF THE PHARMACOKINETICS, EFFICACY, AND SAFETY/TOLERABILITY OF 400 AND 600 MG ONCE-DAILY DOSING OF ACH-1625 (HCV NS3 PROTEASE INHIBITOR) IN HCV GENOTYPE 1

✍ Scribed by V. Detishin; W. Haazen; R. Hooijmaijers; M. Ruppert; K. Bol; H. Robison; L. Robarge; A. Agarwal; M. Deshpande; E. Olek


Book ID
117379603
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
57 KB
Volume
54
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.